SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. LYELa clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that a poster has published the design of the first in-human Phase 1 study of LYL797, Lyell’s ROR1 -targeted CAR-T cell therapy described improved by genetic and epigenetic reprogramming for the treatment of solid tumors will be presented today at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, France.
“This first in-human Phase 1 study is expected to provide important data on the potential of Lyell’s innovative reprogramming technologies to endow T cells with durable antitumor function,” said Dr. Tina Albertson, Lyell’s Chief Medical Officer. “These reprogramming technologies are designed to overcome the primary barriers to sustained response to adoptive cell therapy in patients with solid tumors, namely T-cell depletion and lack of sustained stimulation.”
Details of the presentation are below:
Phase 1 study of LYL797, a ROR1-targeted CAR-T cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors
- Category: test immunotherapy
- Date, time & place: September 12, 2022, 9:00 a.m. CET to 5:00 p.m. CET, Hall 4
- Presentation number: 777TiP
About LYL797
LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) solid tumors. LYL797 contains Gen-R™ and Epi-R™, Lyell’s novel reprogramming technologies designed to overcome the key obstacles to successful adoptive cell therapy: T cell depletion and lack of sustained stimulation. The Phase 1 study will evaluate LYL797 in patients with relapsed/refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). For more information, see ClinicalTrials.gov by searching for NCT05274451.
About Lyell Immunopharma,…
